The US Court of Appeals for the Federal Circuit has affirmed US Patent Trial and Appeal Board’s decisions upholding three patents related to Teva Pharmaceutical’s migraine drug Ajovy, but has invalidated six others.
The US Court of Appeals for the Federal Circuit has affirmed a Delaware court ruling upholding the validity of cancer drug patents owned by Teva Pharmaceuticals.
The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.
Pharmaceutical companies Shionogi and Duchesnay have filed a second lawsuit against Hetero labs, claiming that the company infringed two additional patents related to Osphena—a treatment for vaginal pain during sex.
Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.
The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.
The Delhi High Court has cleared the way for a slew of generic diabetes drugs to arrive on the Indian market after it rejected AstraZeneca’s request for a blocking order.
The UK’s Competition and Markets Authority has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.
An executive order by President Joe Biden has targeted anti-competitive practices in the US drugs market, including a ban of pay-for-delay agreements.
US prosecutors have charged the founders of Taiwanese biosimilar manufacturer JHL Biotech with stealing Genentech trade secrets.